409 related articles for article (PubMed ID: 33750926)
1. Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders.
Chen Y; Wen R; Yang Z; Chen Z
Gene Ther; 2022 May; 29(5):207-216. PubMed ID: 33750926
[TBL] [Abstract][Full Text] [Related]
2. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
Bloomer H; Smith RH; Hakami W; Larochelle A
Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
[TBL] [Abstract][Full Text] [Related]
3. A Versatile Tool for the Quantification of CRISPR/Cas9-Induced Genome Editing Events in Human Hematopoietic Cell Lines and Hematopoietic Stem/Progenitor Cells.
Jayavaradhan R; Pillis DM; Malik P
J Mol Biol; 2019 Jan; 431(1):102-110. PubMed ID: 29751014
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
5. Precision genome editing in the CRISPR era.
Salsman J; Dellaire G
Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
[TBL] [Abstract][Full Text] [Related]
6. Application of genome editing technologies to the study and treatment of hematological disease.
Pellagatti A; Dolatshad H; Yip BH; Valletta S; Boultwood J
Adv Biol Regul; 2016 Jan; 60():122-134. PubMed ID: 26433620
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 in genome editing: Its function and medical applications.
Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
[TBL] [Abstract][Full Text] [Related]
9. Target binding and residence: a new determinant of DNA double-strand break repair pathway choice in CRISPR/Cas9 genome editing.
Feng Y; Liu S; Chen R; Xie A
J Zhejiang Univ Sci B; 2021 Jan; 22(1):73-86. PubMed ID: 33448189
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas systems: ushering in the new genome editing era.
Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
[TBL] [Abstract][Full Text] [Related]
11. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
Shin HR; Kweon J; Kim Y
Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
13. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
14. [CRISPR/CAS9, the King of Genome Editing Tools].
Bannikov AV; Lavrov AV
Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
[TBL] [Abstract][Full Text] [Related]
15. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
16. Optimization of genome editing through CRISPR-Cas9 engineering.
Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
[TBL] [Abstract][Full Text] [Related]
17. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
Kim D; Luk K; Wolfe SA; Kim JS
Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
[TBL] [Abstract][Full Text] [Related]
18. Precise and Predictable CRISPR Chromosomal Rearrangements Reveal Principles of Cas9-Mediated Nucleotide Insertion.
Shou J; Li J; Liu Y; Wu Q
Mol Cell; 2018 Aug; 71(4):498-509.e4. PubMed ID: 30033371
[TBL] [Abstract][Full Text] [Related]
19. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
Swartjes T; Staals RHJ; van der Oost J
Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
